Rapid Acceleration of Diagnostics (RADx) Tech Project #6139: Revogene SARS-CoV-2 Assay
Award Notice Posted
- Solicitation number
- 75N92021C00003
- Agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Awarded
- to Meridian Bioscience Inc.
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75N92021C00003 Federal contract award
- NAICS code
- 334516 Analytical Laboratory Instrument Manufacturing
- PSC
- Q301 Reference Laboratory Testing
- Place of performance
- Cincinnati OH 45244 USA
Notice details come from SAM.gov. Updated .
About this opportunity
This firm fixed price contract for $5,505,000 was awarded by the Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute to MERIDIAN BIOSCIENCE, INC. on February 1, 2021. The contract is to provide 550,000 Revogene SARS-CoV-2 assays under the Rapid Acceleration of Diagnostics Tech Project #6139, which was awarded under the authority of 41 U.S.C 253(c)(1) to address the unusual and compelling urgency presented by the COVID-19 pandemic.
Notice text
This acquisition was awarded under the authority of 41 U.S.C 253(c)(1) as set forth in FAR 6.302-2 unusual and
compelling urgency. A firm fixed price type contract was awarded.
Awarded contract 75N92021C00003 to MERIDIAN BIOSCIENCE, INC. for 5505000.00 on 2021-02-01.
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity